Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

By J. Cauley, J. Robbins, Zhao Chen, Steve Cummings, R. Jackson, A. LaCroix, M. LeBoff, C. Lewis, J. McGowan, J. Neuner and 4 more. Journal of the American Medical Association (JAMA), 2003

1,259 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Oncology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/87aff712ab6ffb432cd259ab4c5382ef71b37d78

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Orthopedics and Sports Medicine

Citations in the corpus

European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2008, background): “Results from observational studies and randomised placebo controlled trials have shown that oestrogens decrease the risk of vertebral and non-vertebral fractures (including hip fracture) by about 30 %, regardless of baseline BMD [158, 228, 229].”
Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands (2004, background): “The finding of a rapid onset and offset of the effect of hormone therapy on fracture, along with the lack of any substantial difference in effect according to the type of hormone used, is in keeping with the effects of hormone therapy on bone mineral density.(1,18-20) The RR of hip fracture in curre”
European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2018, background): “Results from observational studies and randomised placebo-controlled trials have shown that estrogens decrease the risk of vertebral and nonvertebral fractures (including hip fracture) by about 30%, regardless of baseline BMD [272, 273].”